Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:SCPS OTCMKTS:SPHS NASDAQ:VRPX OTCMKTS:XSNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSCPSScopus BioPharma$0.00+66.7%$0.00$0.00▼$0.01$21K-0.181,815 shs204 shsSPHSSophiris Bio$0.00$0.00▼$0.05$4K1.94N/AN/AVRPXVirpax Pharmaceuticals$0.01-9.8%$0.19$0.01▼$26.25$14K1.49167,984 shs3,076 shsXSNXNovAccess Global$0.00$0.00$0.00▼$0.02$13K3.21214 shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSCPSScopus BioPharma0.00%0.00%0.00%0.00%0.00%SPHSSophiris Bio0.00%0.00%0.00%0.00%0.00%VRPXVirpax Pharmaceuticals0.00%+11.82%-41.43%-94.65%-99.94%XSNXNovAccess Global0.00%0.00%+200.00%-25.00%-94.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationSCPSScopus BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AXSNXNovAccess GlobalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSCPSScopus BioPharma 0.00N/AN/AN/ASPHSSophiris Bio 0.00N/AN/AN/AVRPXVirpax Pharmaceuticals 2.00HoldN/AN/AXSNXNovAccess Global 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSCPSScopus BioPharmaN/AN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/A$1.65 per shareN/AXSNXNovAccess GlobalN/AN/AN/AN/A($0.58) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSCPSScopus BioPharma-$11.61MN/A0.00∞N/AN/AN/AN/AN/ASPHSSophiris BioN/AN/A0.00N/AN/AN/AN/AN/AN/AVRPXVirpax Pharmaceuticals-$15.19MN/A0.00∞N/AN/A-1,554.34%-338.29%N/AXSNXNovAccess Global-$4.72M-$0.11N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthSCPSScopus BioPharmaN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/AN/AXSNXNovAccess GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSCPSScopus BioPharmaN/AN/AN/ASPHSSophiris BioN/AN/AN/AVRPXVirpax PharmaceuticalsN/A0.130.13XSNXNovAccess GlobalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSCPSScopus BioPharmaN/ASPHSSophiris BioN/AVRPXVirpax Pharmaceuticals32.23%XSNXNovAccess GlobalN/AInsider OwnershipCompanyInsider OwnershipSCPSScopus BioPharma5.10%SPHSSophiris Bio4.50%VRPXVirpax Pharmaceuticals3.70%XSNXNovAccess Global1.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableSCPSScopus BioPharma942.08 million39.94 millionNot OptionableSPHSSophiris Bio635.55 millionN/ANot OptionableVRPXVirpax Pharmaceuticals71.24 million4.71 millionNot OptionableXSNXNovAccess Global244.60 million43.96 millionNot OptionableSPHS, VRPX, XSNX, and SCPS HeadlinesRecent News About These CompaniesGlobal wage calculator: Compare your salaryNovember 14, 2024 | money.cnn.comNovAccess Global Inc.August 28, 2024 | wsj.comNovAccess Global Inc. (XSNX)July 21, 2024 | finance.yahoo.comNovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine PlatformMay 21, 2024 | finance.yahoo.comNovAccess Global Inc.: NovAccess Global Advisory on Annual Meeting of ShareholdersMay 7, 2024 | finanznachrichten.deNovAccess Global Advisory on Annual Meeting of ShareholdersMay 7, 2024 | accesswire.comANovAccess Global Announces New License to Advance its Immunotherapy PlatformApril 30, 2024 | finance.yahoo.comNovAccess Global Announces New License to Advance its Immunotherapy PlatformApril 30, 2024 | accesswire.comANovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of ShareholdersMarch 1, 2024 | accesswire.comANovAccess Global Faces Default and Uncertain Rescue DealFebruary 7, 2024 | msn.comNovAccess Global jumps on announcing $10.7 million financingJanuary 2, 2024 | msn.comNovAccess Global Inc.: NovAccess Global Announces $10.7 Million FinancingJanuary 2, 2024 | finanznachrichten.deNovAccess Global Announces $10.7 Million FinancingJanuary 2, 2024 | finance.yahoo.comNovAccess Global Inc. to Present at the December 7th Virtual Investor SummitDecember 1, 2023 | finance.yahoo.comNovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory BoardNovember 10, 2023 | finance.yahoo.comNovaccess Global Inc XSNXNovember 2, 2023 | morningstar.comMBack to the Trend? Global Debt Evolution Before and After the PandemicSeptember 13, 2023 | imf.orgINovAccess Global Inc.: NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 29, 2023 | finanznachrichten.deNovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 27, 2023 | finance.yahoo.comNovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness DayJuly 13, 2023 | finance.yahoo.comSPHS, VRPX, XSNX, and SCPS Company DescriptionsScopus BioPharma NASDAQ:SCPS$0.0005 +0.00 (+66.67%) As of 02:12 PM EasternScopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.Sophiris Bio OTCMKTS:SPHSSophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.Virpax Pharmaceuticals NASDAQ:VRPX$0.01 0.00 (-9.76%) As of 10:33 AM EasternVirpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.NovAccess Global OTCMKTS:XSNX$0.0003 0.00 (0.00%) As of 08/22/2025NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an Entry Super Micro Computer Stock Hasn't Priced in Growth Yet Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Why Zuckerberg's META Sales Look More Bullish Than Bearish 3 Dividend Growth Leaders to Buy Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access